Compare DSX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | AKBA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Greece | United States |
| Employees | 939 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.1M | 251.0M |
| IPO Year | N/A | 2014 |
| Metric | DSX | AKBA |
|---|---|---|
| Price | $2.22 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 616.8K | ★ 5.5M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.28 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $0.82 |
| 52 Week High | $2.92 | $4.02 |
| Indicator | DSX | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 55.49 |
| Support Level | $2.17 | $1.16 |
| Resistance Level | $2.24 | $1.54 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 90.00 | 48.68 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.